Research Article
Survival Analysis of Radiation Therapy in Ovarian Cancer: A SEER Database Analysis
Table 1
Baseline characteristics of patients with ovarian cancer before and after propensity score matching analysis.
| | | Total (N = 20031) | Before PSM | After PSM | | Non-RT (N = 19740) | RT (N = 291) | value | Non-RT (N = 218) | RT (N = 218) | value |
| | Age, y, median (IQR) | 59 (50–68) | 59 (50–68) | 59 (50–70) | 0.387 | 58 (49–68) | 58 (49–68) | 0.786 | | ≤40 | 2056 (10.26%) | 2030 (10.28%) | 26 (8.93%) | 0.640 | 102 (46.79%) | 107 (49.08%) | 0.784 | | 40–60 | 8903 (44.45%) | 8767 (44.41%) | 136 (46.74%) | — | 24 (11.01%) | 20 (9.17%) | — | | >60 | 9072 (45.29%) | 8943 (45.30%) | 129 (44.33%) | — | 92 (42.20%) | 91 (41.74%) | — |
| | Race | | | | 0.031 | | | 0.096 | | White | 16221 (80.98%) | 16001 (81.06%) | 220 (75.60%) | — | 162 (74.31%) | 169 (77.52%) | — | | Black | 1589 (7.93%) | 1553 (7.87%) | 36 (12.37%) | — | 13 (5.96%) | 20 (9.17%) | — | | Others | 2094 (10.45%) | 2060 (10.44%) | 34 (11.68%) | — | 43 (19.72%) | 28 (12.84%) | — | | UNK | 127 (0.63%) | 126 (0.64%) | 1 (0.34%) | — | 0 | 1 (0.46%) | — |
| | Marital status | | | | 0.545 | | | 0.927 | | Married | 10468 (52.26%) | 10323 (52.29%) | 145 (49.83%) | — | 112 (51.38%) | 115 (52.75%) | — | | Never married | 4207 (21.00%) | 4141 (20.98%) | 66 (22.68%) | — | 46 (21.10%) | 49 (22.48%) | — | | Other | 4430 (22.12%) | 4360 (22.09%) | 70 (24.05%) | — | 54 (24.77%) | 48 (22.02%) | — | | UNK | 926 (4.62%) | 916 (4.64%) | 10 (3.44%) | — | 6 (2.75%) | 6 (2.75%) | — |
| | Insurance | | | | 0.853 | | | 0.182 | | No | 761 (3.80%) | 750 (3.80%) | 11 (3.78%) | — | 2 (0.92%) | 7 (3.21%) | — | | Yes | 18951 (94.61%) | 18677 (94.61%) | 274 (94.16%) | — | 214 (98.17%) | 208 (95.41%) | — | | UNK | 319 (1.59%) | 313 (1.59%) | 6 (2.06%) | — | 2 (0.92%) | 3 (1.38%) | — |
| | Laterality | | | | <0.001 | | | 0.077 | | Unilateral | 11610 (57.96%) | 11468 (58.10%) | 142 (48.80%) | — | 121 (55.50%) | 125 (57.34%) | — | | Bilateral | 7504 (37.46%) | 7426 (37.62%) | 78 (26.80%) | — | 82 (37.61%) | 66 (30.28%) | — | | UNK | 917 (4.58%) | 846 (4.29%) | 71 (24.40%) | — | 15 (6.88%) | 27 (12.39%) | — |
| | Tumor size, mm | | | | <0.001 | | | 0.156 | | ≤50 | 3881 (19.37%) | 3838 (19.44%) | 43 (14.78%) | — | 42 (19.27%) | 33 (15.14%) | — | | 50–100 | 4770 (23.81%) | 4711 (23.87%) | 59 (20.27%) | — | 54 (24.77%) | 54 (24.77%) | — | | 100–200 | 5867 (29.29%) | 5792 (29.34%) | 75 (25.77%) | — | 48 (22.02%) | 63 (28.90%) | — | | >200 | 1263 (6.31%) | 1246 (6.31%) | 17 (5.84%) | — | 8 (3.67%) | 15 (6.88%) | — | | UNK | 4250 (21.22%) | 4153 (21.04%) | 97 (33.33%) | — | 66 (30.28%) | 53 (24.31%) | — |
| | Pathology | | | | <0.001 | | | <0.001 | | Epithelial | 15360 (76.68%) | 15223 (77.12%) | 137 (47.08%) | — | 156 (71.56%) | 119 (54.59%) | — | | Not epithelial | 4671 (23.32%) | 4517 (22.88%) | 154 (52.92%) | — | 62 (28.44%) | 99 (45.41%) | — |
| | Grade | | | | <0.001 | | | 0.192 | | G1 | 1660 (8.29%) | 1653 (8.37%) | 7 (2.41%) | — | 15 (6.88%) | 6 (2.75%) | — | | G2 | 2423 (12.10%) | 2408 (12.20%) | 15 (5.15%) | — | 21 (9.63%) | 14 (6.42%) | — | | G3 | 6429 (32.10%) | 6322 (32.03%) | 107 (36.77%) | — | 82 (37.61%) | 92 (42.20%) | — | | G4 | 4885 (24.39%) | 4833 (24.48%) | 52 (17.87%) | — | 43 (19.72%) | 48 (22.02%) | — | | UNK | 4634 (23.13%) | 4524 (22.92%) | 110 (37.80%) | — | 57 (26.15%) | 58 (26.61%) | — |
| | SEER combined summary stage | | | | <0.001 | | | <0.001 | | | Local | 3708 (18.51%) | 3700 (18.74%) | 8 (2.75%) | — | 37 (16.97%) | 8 (3.67%) | — | | Regional | 4874 (24.33%) | 4793 (24.28%) | 81 (27.84%) | — | 50 (22.94%) | 73 (33.49%) | — | | Distant | 11234 (56.08%) | 11037 (55.91%) | 197 (67.70%) | — | 128 (58.72%) | 133 (61.01%) | — | | UNK | 215 (1.07%) | 210 (1.06%) | 5 (1.72%) | — | 3 (1.38%) | 4 (1.83%) | — |
| | AJCC stage | | | | <0.001 | | | <0.001 | | I | 5827 (29.09%) | 5806 (29.41%) | 21 (7.22%) | — | 60 (27.52%) | 21 (9.63%) | — | | II | 1956 (9.76%) | 1915 (9.70%) | 41 (14.09%) | — | 15 (6.88%) | 40 (18.35%) | — | | III | 7962 (39.75%) | 7893 (39.98%) | 69 (23.71%) | — | 77 (35.32%) | 61 (27.98%) | — | | IV | 3910 (19.52%) | 3764 (19.07%) | 146 (50.17%) | — | 59 (27.06%) | 86 (39.45%) | — | | UNK | 376 (1.88%) | 362 (1.83%) | 14 (4.81%) | — | 7 (3.21%) | 10 (4.59%) | — |
| | T | | | | <0.001 | | | <0.001 | | T0 | 29 (0.14%) | 20 (0.10%) | 9 (3.09%) | — | 1 (0.46%) | 1 (0.46%) | — | | T1 | 6261 (31.26%) | 6225 (31.53%) | 36 (12.37%) | — | 73 (33.49%) | 34 (15.60%) | — | | T2 | 2745 (13.70%) | 2663 (13.49%) | 82 (28.18%) | — | 26 (11.93%) | 66 (30.28%) | — | | T3 | 10500 (52.42%) | 10380 (52.58%) | 120 (41.24%) | — | 102 (46.79%) | 97 (44.50%) | — | | Tx/NA | 496 (2.48%) | 452 (2.29%) | 44 (15.12%) | — | 16 (7.34%) | 20 (9.17%) | — |
| | N | | | | <0.001 | | | 0.343 | | N0 | 14628 (73.03%) | 14477 (73.34%) | 151 (51.89%) | — | 137 (62.84%) | 125 (57.34%) | — | | N1 | 4273 (21.33%) | 4178 (21.17%) | 95 (32.65%) | — | 58 (26.61%) | 72 (33.03%) | — | | Nx/NA | 1130 (5.64%) | 1085 (5.50%) | 45 (15.46%) | — | 23 (10.55%) | 21 (9.63%) | — |
| | M | | | | <0.001 | | | 0.022 | | M0 | 16062 (80.19%) | 15920 (80.65%) | 142 (48.80%) | — | 155 (71.10%) | 129 (59.17%) | — | | M1 | 3910 (19.52%) | 3764 (19.07%) | 146 (50.17%) | — | 59 (27.06%) | 86 (39.45%) | — | | NA | 59 (0.29%) | 56 (0.28%) | 3 (1.03%) | — | 4 (1.83%) | 3 (1.38%) | — |
| | Metastasis | | | | | | | | | Bone | 99 (0.49%) | 61 (0.31%) | 38 (13.06%) | <0.001 | 1 (0.46%) | 18 (8.26%) | <0.001 | | Brain | 33 (0.16%) | 7 (0.04%) | 26 (8.93%) | <0.001 | 0 | 13 (5.96%) | <0.001 | | Liver | 893 (4.46%) | 854 (4.33%) | 39 (13.40%) | <0.001 | 13 (5.96%) | 20 (9.17%) | 0.139 | | Lung | 704 (3.51%) | 666 (3.37%) | 38 (13.06%) | <0.001 | 17 (7.80%) | 19 (8.72%) | 0.877 |
| | Surgery | | | | <0.001 | | | 1.000 | | Yes | 19902 (99.36%) | 19705 (99.82%) | 197 (67.70%) | — | 197 (90.37%) | 197 (90.37%) | — | | No | 129 (0.64%) | 35 (0.18%) | 94 (32.30%) | — | 21 (9.63%) | 21 (9.63%) | — |
| | Chemotherapy | | | | 0.006 | | | 0.014 | | Yes | 14976 (74.76%) | 14738 (74.66%) | 238 (81.79%) | — | 160 (73.39%) | 182 (83.49%) | — | | No/UNK | 5055 (25.24%) | 5002 (25.34%) | 53 (18.21%) | — | 58 (26.61%) | 36 (16.51%) | — |
| | CA125, U/mL | | | | 0.085 | | | 0.001 | | Normal | 2117 (10.57%) | 2089 (10.58%) | 28 (9.62%) | — | 38 (17.43%) | 24 (11.01%) | — | | Elevated | 13444 (67.12%) | 13264 (67.19%) | 180 (61.86%) | — | 146 (66.97%) | 130 (59.63%) | — | | Borderline | 28 (0.14%) | 28 (0.14%) | 0 | — | 0 | 0 | — | | UNK | 4442 (22.18%) | 4359 (22.08%) | 83 (28.52%) | — | 34 (15.60%) | 64 (29.36%) | — |
|
|
Abbreviations: PSM: propensity score matching; RT: radiotherapy; IQR: interquartile range; UNK: unknown; NA: not applicable.
|
